Follow-up analyses of the RV144 trial of Sanofi SA's ALVAC HIV and VaxGen Inc.'s AIDSVAX B/E HIV vaccine by a team from Duke University has provided evidence that the competition of two different types of antibodies may have lowered the efficacy of the vaccine.